PAREXEL International Corporation (NASDAQ: PRXL) provides contract research, medical marketing and consulting services to the pharmaceutical, biotechnology and medical device industries. Its Clinical Research Services segment offers clinical trial and data management, clinical pharmacology and related medical advisory services. The Consulting and Medical Communications Services unit offers technical advice on new product development, marketing and regulatory affairs. Subsidiary Perceptive Informatics sells IT system, medical imaging, and related services that help manage clinical trials.

The company pleased investors last week, when it guided fiscal Q4 EPS to 25-26 cents and revenues to $258-$265 million. Analysts had been looking for 26 cents and $259.31 million. Management also guided FY09 EPS to $1.10-$1.20 ($1.08 consensus) and FY09 revenues to $1.11-$1.14 billion ($1.14B consensus). Raymond James subsequently upgraded the stock to "outperform", noting that the firm "will exhibit a strong growth profile due to a strong biopharmaceutical outsourcing market, a large geographic footprint and a diversified service offering."

Continue reading PAREXEL International (PRXL): Price consolidating in bullish 'pennant' pattern

PAREXEL International (PRXL): Price consolidating in bullish 'pennant' pattern originally appeared on BloggingStocks on Mon, 30 Jun 2008 12:15:00 EST. Please see our terms for use of feeds.

PAREXEL International Corporation (NASDAQ: PRXL) provides contract research, medical marketing and consulting services to the pharmaceutical, biotechnology and medical device industries. Its Clinical Research Services segment offers clinical trial and data management, clinical pharmacology and related medical advisory services. The Consulting and Medical Communications Services unit offers technical advice in new product development, marketing, and regulatory affairs. Subsidiary Perceptive Informatics sells IT system, medical imaging, and related services that help manage clinical trials.

The company pleased investors last week, when it reported fiscal Q2 EPS of 40 cents and revenues of $284.2 million. Analysts had been looking for 39 cents and $222.8 million. The CEO noted that revenue growth was driven by improvements across all business and geographic reporting segments. Management also guided Q3 EPS to 42-44 cents (43 cent consensus), Q3 revenues to $240-$250 million ($232.11M consensus), FY08 EPS to $1.78-$1.83 ($1.65 consensus) and FY08 revenues to $935-$955 million ($907.20M consensus).

Continue reading PAREXEL International (PRXL): Shares defing bullish 'flag' formation

PAREXEL International (PRXL): Shares defing bullish 'flag' formation originally appeared on BloggingStocks on Tue, 29 Jan 2008 11:24:00 EST. Please see our terms for use of feeds.